1/When insurers *deny* coverage of buprenorphine for OUD care based on "lack of documented counseling", they ENFORCE a policy that is opposite to national recommendations. #addiction#OUD
2/The @ASAMorg guideline (2020) for opioid use disorder lays out a strong case FOR "psychosocial treatment"
AND it ALSO declares that precluding bupe based on declining counseling puts the patient's life at risk …tefinitystorage.blob.core.windows.net/sitefinity-pro…
3/The reason is obvious. A patient with diagnosed OUD and loss of access to medication is at risk of use of illicitly sourced opioids and death.
Withholding the life-saving medication is a bad idea.
This doesn't mean "counseling is no good", but it's not "requirable"
4/There are 4 trials finding psychological counseling offered NO additional benefit beyond Bupe Rx for OUD, but data don't all fall one way.
Some behavioral treatments (contingency management) *do* confer additional benefit. A great review here: focus.psychiatryonline.org/doi/10.1176/ap…
5/Finally, I'll note that SOME state laws also require counseling, even if the evidence for that mandate is non-existent, as reported by @AndrakaBasia in J. Addiction Medicine this year :journals.lww.com/journaladdicti…
6/In short, if an insurer or state law urges withholding a medication in absence of documented "counseling", there is no evidence for that view and it is opposed by major national guidelines. Some forms of behavioral treatment may still be important and helpful /fin
T
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1/Suprising to see:
Rx Opioids, combined with benzodiazepines, *usually do* substantially increase overdose risk, but- seemingly- not for people at 25-50 MME & 10-20 diazepam equivalents daily, in analysis of US Medicare data in @AddictionJrnl onlinelibrary.wiley.com/doi/10.1111/ad…
2/Authors calculated 9 distinct 6-month trajectories for opioid Rx, taking dose of opioids and benzodiazepines into account. These included 3 where the opioids were stopped in <3 months "very low".
3/The people at 51-90 MME ( called "moderate") AND benzodiazepines dosing that was low (10-20 diazepam equivalents daily) were at four-fold increased risk, in relative terms, of opioid overdose
1/Out TODAY: the 10th paper reporting adverse associations between Rx opioid reduction & patient safety, this on by @fenton_jj @AllysonVarley & I come in @JAMA_Open
“New Data on Opioid Dose Reduction – Implications for Patient Safety”
2/In truth prescribers are under pressure to ⬇️ doses due to investigations & @NCQA quality metrics: here a Med Board says if the patients is at 90 mg, surely they can be tried at 50 (“they’re not gonna like it”) -but they don’t address the safety youtube.com/clip/Ugkxgre9S…
3/Many prior database studies find poor outcomes among tapered patients. But all do have a limitation:
If MD’s reduced doses *in reaction to clinical instability* in their patients, then instability AFTER dose reductions might *not be attributable* to the dose reduction itself
1/This superb article raises up the validity problems, implementation challenges, and potential risks (& lack of benefit) of the proprietary "NarxCare" score packaged with prescription drug monitoring programs
2/It's important to note that seeing what prescriptions a patient receives helps me as a doctor. The @BambooHLTH NarxCare score uses some combination of variables visible to PDMPs to devise a "risk", but there are validity problems with its inputs, and problems with its output
3/Validity: I work in an academic practice for Veterans. Under strict & regular protocols, a group shares responsibility for Rx's. But as we are a *group*, every one of our patients is scored adversely by Bamboo with higher NarxCare score, as if they were doctor-shoppers.
1/Medical hospitalization is a “window of opportunity” for patients with opioid use disorder to potentially start medication treatment for OUD- but you can’t necessarily switch from full agonist (after major )surgery to bupe- Dr Amy Kennedy
2/A low dose induction allows the patient to continue the full dose agonist - gradually increasing buprenorphine while continuing the full opioid agonist. Limited evidence however.
1/Drug overdose deaths for 2021 rose 15% nationally, to 107,622 (projected after data is 100% complete) - according to CDC, and jumping by 30% in Alabama to 1312.
I'll offer a few reflections on a bad situation and my thoughts on what communities should do
2/For overdose deaths that have a drug identified, 74% include an opioid.
- 88% of opioid deaths include a "synthetic opioid" - typically fentanyl but also isotonitazine and brorphine. Only 12% of opioid deaths lack a fentanyl type drug.
1/🚨Addiction & Substance Use Science of 2021🚨
Our #SGIM22 team checked >1000 titles to come up with key insights for general med/addiction clinicians and affected communities on:
Opioids
Alcohol
“Potpourri” (nicotine, stimulants+)
Policy
Let's go! @SocietyGIM
3/*Tired of docs who don’t know anything about addiction?
Internal Medicine resident training in addiction WILL be required starting 7/1/22, –
But this paper finds some training but only 12% include addiction med clinic time pubmed.ncbi.nlm.nih.gov/34729698/